• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, September 5, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

A chemical tailor-made suit for Alzheimer’s drugs

Bioengineer by Bioengineer
July 17, 2020
in Science News
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Research team from Göttingen and Halle develops new inhibitors for enzymes

IMAGE

Credit: Lisa-Marie Funk

With over 1.2 million people affected in Germany alone and over 50 million people worldwide, Alzheimer’s disease, also referred to simply as Alzheimer’s, is one of the greatest medical and social challenges of our time. Due to pathological changes in the brain, patients become increasingly forgetful and disoriented as the disease progresses. In the worst cases, even close relatives are no longer recognized and simple household tasks can no longer be carried out independently. This means care is needed for those affected. Despite intensive research, Alzheimer’s disease is still considered incurable today. Researchers at the University of Göttingen and the Fraunhofer Institute for Cell Therapy and Immunology Leipzig-Halle have described a promising approach to treating Alzheimer’s disease. The results have been published in the journal Biochemistry.

For the study, Professor Kai Tittmann from the Göttingen Centre for Molecular Biosciences worked together with researchers from the Faculty of Chemistry at the University of Göttingen and the team led by Professor Hans-Ulrich Demuth from Fraunhofer IZI in Halle. Several years ago, the team from Halle discovered that a specific enzyme that is part of the human brain’s hormone metabolism plays a critical pathophysiological role in the development of Alzheimer’s disease, in addition to its actual biological function of hormone maturation. The first inhibitors of this enzyme, which inhibit specific pathological processes, have already produced promising results.

In order to give these active ingredients a chemical “tailor-made suit”, the research team investigated the enzyme’s reaction mechanism using protein crystallography. “This enabled us to obtain ‘snapshots’ of the working enzyme for the first time,” says senior author Tittmann. This made it possible to build novel inhibitors where the principle of the design is based on the natural reaction. These inhibitors therefore lead to highly selective binding without the risk of dangerous side effects. The scientists also succeeded in determining an atomic structure of the human enzyme with the new substance. This forms an important basis for further development of the inhibitors. “We are confident that our results will lead to the development of a new, highly selective generation of Alzheimer’s drugs,” explained Demuth.

###

The research project was funded by the German Research Foundation (DFG), the Federal Ministry of Economic Affairs and Energy and the Alzheimer Forschung Initiative e.V.

Original publication: Oliver Kupski et al. Hydrazides Are Potent Transition-State Analogues for Glutaminyl Cyclase Implicated in the Pathogenesis of Alzheimer’s Disease. Biochemistry (2020). https://pubs.acs.org/doi/10.1021/acs.biochem.0c00337

DOI: 10.1021/acs.biochem.0c00337

Contact:

Professor Kai Tittmann

University of Göttingen

Molecular Enzymology Group

Julia-Lermontowa-Weg 3, 37077 Göttingen, Germany

Tel: +49 (0)551 39177811

Email: [email protected]

http://www.uni-goettingen.de/en/sh/198266.html

Professor Hans-Ulrich Demuth

Fraunhofer Institute for Cell Therapy and Immunology (IZI)

Drug Design and Target Validation Department

Weinbergweg 22, 06120 Halle/Saale, Germany

Tel: +49 (0)345 131428-15

Email: [email protected]

https://www.izi.fraunhofer.de/en/departments/halle-location/department-of-drug-design-and-target-validation.html

Media Contact
Melissa Sollich
[email protected]

Original Source

https://www.uni-goettingen.de/en/3240.html?id=5943

Related Journal Article

http://dx.doi.org/10.1021/acs.biochem.0c00337

Tags: AlzheimerBiochemistryBiologyBiomedical/Environmental/Chemical EngineeringBiotechnologyCell BiologyChemistry/Physics/Materials SciencesMedicine/HealthMolecular Biologyneurobiology
Share12Tweet8Share2ShareShareShare2

Related Posts

Addressing Emerging Pollutants in China: An In-Depth Review of Current Challenges, Knowledge Gaps, and Strategic Solutions

September 5, 2025
Microwave-Assisted Synthesis of Biomass-Derived N-Doped Carbon Dots Advances Metal Ion Sensing Technology

Microwave-Assisted Synthesis of Biomass-Derived N-Doped Carbon Dots Advances Metal Ion Sensing Technology

September 5, 2025

Enduring Benefits of OR Shadowing for New Nurses

September 5, 2025

Revolutionizing CAR Therapy for Thyroid Eye Disease

September 5, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    149 shares
    Share 60 Tweet 37
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    115 shares
    Share 46 Tweet 29
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    61 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Addressing Emerging Pollutants in China: An In-Depth Review of Current Challenges, Knowledge Gaps, and Strategic Solutions

Microwave-Assisted Synthesis of Biomass-Derived N-Doped Carbon Dots Advances Metal Ion Sensing Technology

Enduring Benefits of OR Shadowing for New Nurses

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.